Iteos Therapeutics Inc

Iteos Therapeutics — Investor Presentation (November 2020)

27 slides from Iteos Therapeutics's investor presentation, Nov 12, 2020

  1. Slide 1: Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression

    Pioneering Novel IO Therapies Focused on Key Mechanisms of Immunosuppression November 2020 Exhibit 99.3

  2. Slide 2: Disclaimer

    Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical f

  3. Slide 3: Key Investment Highlights

    Key Investment Highlights Developing next generation IO therapeutics, targeting key mechanisms of immunosuppression Multiple near-term clinical and pipeline milestones EOS-850 is a potential best-in-class selective A2AR antagonist with two confirmed PRs in Phase 1 single agent dose escalation Pipeli

  4. Slide 4: Our Leadership Team

    Our Leadership Team Matt Call Chief Operating Officer Joanne Lager, M.D. Chief Medical Officer Michel Detheux, Ph.D. President & CEO Matthew Gall Chief Financial Officer Leadership Team Yvonne McGrath, Ph.D. Vice President, R&D Board of Directors David Hallal, Chair CEO Elevate Bio Michel Detheux CE

  5. Slide 5: Our Lead Candidates Target A2A Receptor and TIGIT

    Activated Immune Cell Our Lead Candidates Target A2A Receptor and TIGIT EOS-448: Anti-TIGIT Immunotherapy 1 2 EOS-448 CD226 receptor TIGIT receptor FcγR Treg Cell TIGIT receptors ENHANCED IMMUNE RESPONSE Blocking A2AR prevents inhibition of T cell activation EOS-850: A2A Receptor1 Blockade Immunothe

  6. Slide 6: Pipeline of Targeted Immuno-Oncology Product Candidates

    Pipeline of Targeted Immuno-Oncology Product Candidates Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Phase 2/3 Key upcoming milestones Worldwide rights Adenosine A2A Receptor Antagonist EOS-850 Monotherapy Solid Tumors Initial expansion results 1H 2021 + pembrolizumab Anti-PD-1-R

  7. Slide 7: EOS-850 Potentially Best-in-Class Adenosine Receptor Antagonist

    Phase 1/2 Program with Early Single Agent Activity EOS-850 Potentially Best-in-Class Adenosine Receptor Antagonist

  8. Slide 8: High Adenosine Concentrations Prevent an Anti-Tumor Immune Response

    High Adenosine Concentrations Prevent an Anti-Tumor Immune Response Across a Wide Range of Tumor Types High levels of adenosine in TME1 due to hypoxia and necrosis suppress effector T cells Immunosuppression 1 2 Activation of immune response Activated Effector T Cell EOS-850 TUMOR CELL A2A receptor

  9. Slide 9: EOS-850 has a Differentiated PK/PD Profile

    EOS-850 has a Differentiated PK/PD Profile 3mg/kg oral dosing High affinity for A2AR and insurmountable antagonism Designed to minimize blood-brain barrier penetration 1 3 Prolonged PD effect and sustained A2AR inhibition Designed to avoid potential toxicities from targeting alternate receptor subty

  10. Slide 10: EOS-850 has a Potential Best-in-Class Therapeutic Profile

    EOS-850 has a Potential Best-in-Class Therapeutic Profile Generally well tolerated at all dose levels with no DLT1 observed Preliminary evidence of clinical benefit in 7 patients: 2 ongoing confirmed PRs2 Sustained inhibition of A2AR and prolonged PD activity Ongoing tumor profiling and biomarker id

  11. Slide 11: EOS-850 Monotherapy Demonstrated Preliminary Evidence of Clinical Benefit

    EOS-850 Monotherapy Demonstrated Preliminary Evidence of Clinical Benefit in Heavily Pretreated Patients As of 10 Jun 2020 Notes: 1 Once daily doses 2 Twice daily doses CRC: colorectal cancer; NSCLC: non-small-cell lung carcinoma; TCC: transitional cell carcinoma; CRPC: castrate resistant prostate c

  12. Slide 12: Confirmed PR with 44% Tumor Reduction in Metastatic Melanoma

    Heavily pre-treated with multiple CPIs 2 previous cycles of pembro 1 previous cycle of ipi Stable disease at 7 weeks 26% tumor reduction PR at 16 weeks 44% tumor reduction Confirmed PR at 24 weeks Baseline Week 16 Prior Treatments Confirmed PR with 44% Tumor Reduction in Checkpoint Inhibitor-refract

  13. Slide 13: Confirmed PR with 49% Tumor Reduction in Heavily Pretreated mCRPC

    Confirmed PR with 49% Tumor Reduction in Heavily Pretreated mCRPC Stable disease at 8 weeks PR at 16 weeks 40% tumor reduction Confirmed PR at 30 weeks 49% tumor reduction Heavily pretreated with 5 previous rounds of therapy Prior treatments include antiandrogen therapy and 2 lines of chemotherapy F

  14. Slide 14: No DLTs Observed in Dose Escalation; Treatment-Emergent Adverse Events

    21 patients were enrolled at 5 dose levels and completed the dose-limiting toxicity evaluation No DLTs observed in dose escalation Treatment-Emergent Adverse Events (n=21) Drug- Related Any Attribution Number of Patients (%) Any Grade 15 ( 71.4%) 21 (100.0%) Grade 1-2 15 ( 71.4%) 21 (100.0%) Grade 3

  15. Slide 15: EOS-850 Phase 1/2 Clinical Plan

    EOS-850 Phase 1/2 Clinical Plan Single agent Safety and PK/PD Expansion Cohorts Dose Escalation (Completed) Advanced solid tumor patients (n=21) Biomarker-rich study w/matched tumor biopsies +Pembro (Ongoing) Solid Tumors (n=10) +Chemo (Initiating) TNBC (n=6) 1L TNBC (n= up to 38) Anti-PD-1-Resistan

  16. Slide 16: EOS-850 Clinical Strategy: Multi-Pronged Strategy

    EOS-850 Clinical Strategy: Multi-Pronged Strategy Incorporating Speed, Market Size, Rational Combinations PD-L1-Negative TNBC Combination with Chemo 2L mCRPC PD-(L)1 Resistant Melanoma Chemotherapy leads to immunogenic cell death and promotes necrosis and hypoxia that lead to adenosine production Ex

  17. Slide 17: EOS-448 FcγR-engaging Anti-TIGIT Antibody

    Currently in Dose Escalation Phase 1/2 Trial EOS-448 Fc��R-engaging Anti-TIGIT Antibody

  18. Slide 18: EOS-448 is Designed to Enhance Anti-Tumor Immune Response Through Multiple Mechanisms

    EOS-448 is Designed to Enhance Anti-Tumor Immune Response Through Multiple Mechanisms 4 2 3 T cells or NK cells 1 Tumor cell EOS-448 CD112 CD155 CD226 TIGIT FCgR Treg cell NK cell TUMOR ANTIGENS Tumor- specific T cells Macrophage FCgR EOS-448 TIGIT Dead tumor cells Antigen-Presenting Cells (APCs) T

  19. Slide 19: EOS-448's Ability to Block TIGIT is Associated With Superior Immune Activation

    EOS-448's Ability to Block TIGIT is Associated With Superior Immune Activation EOS-448 is associated with superior IL-2 mediated gene expression Mereo = 313M32 from US2016/0376365 A1; Genentech = 4.1D3 from WO2017/053748 A2; BMS = 22G2 from US2016/0176963 A1; Merck = Clone 31C6 from WO2016/028656vA1

  20. Slide 20: FcgR Engagement Enhanced the Anti-Tumor Effect in Monotherapy and in Combination

    High FcgR-engaging isotype in WT mice Low FcgR-engaging isotype in WT mice aPD-1 aTIGIT D10 13 16 aPD-1 aTIGIT D9 12 15 7/8 CR FcgR Engagement Enhanced the Anti-Tumor Effect in Monotherapy and in Combination CT26 Colon Cancer Tumor Model High FcgR-engaging isotype in FcgR KO mice Changing the isotyp

  21. Slide 21: Tregs, Particularly TILs, Express the Highest Level of TIGIT

    TIGIT is expressed in high proportion of circulating CD8+ & Treg cells in cancer patients, with highest density on Tregs TILs Tregs, Particularly TILs, Express the Highest Level of TIGIT, Making Tregs a Preferred Target for Depletion by EOS-448 Highest number of TIGIT molecules on Treg from TME TIGI

  22. Slide 22: FcgR Engagement Led to Preferential Depletion of Tregs

    FcgR Engagement Led to Preferential Depletion of Tregs, while Sparing Most Functional Effector T cells PBMCs isolated from a lung cancer patient TIGIT-expressing TILs have an exhausted phenotype EOS-448 selectively depletes Tregs, sparing most effector T cells Þ Þ Þ Þ 0 20 40 60 p<0.005 p<0.0005 % o

  23. Slide 23: EOS-448 Initial Clinical Plan

    EOS-448 Initial Clinical Plan Single agent Combination PoC Trials Dose Escalation (Ongoing) Advanced solid tumor patients (n=30) Biomarker-rich study w/matched tumor biopsies + anti-PD-1 Solid Tumors + EOS-850 Solid Tumors Complementary mechanisms of immunosuppression Targeting multiple immune cells

  24. Slide 24: Investment Forecast and Near-term Catalysts

    Investment Forecast and Near-term Catalysts iTeos Financials

  25. Slide 25: Investment Forecast

    Investment Forecast SUMMARY September 30, 2020 cash balance of $340MM In July, raised $210.6MM in net proceeds from IPO Cash on hand expected to fund company into second half of 2023 Range of forecast spend MM Well positioned to continue to advance lead programs and invest in further pipeline growth

  26. Slide 26: Strong Cash Position to Fund Progress

    Strong Cash Position to Fund Progress Ongoing Execution Provides Several Catalysts over Near-term Horizon. Potential cash runway well into 2023 provides ability to fund randomized trials. EOS-850 EOS-448 Preliminary results of expansion cohorts (Safety and Efficacy) Phase 1 dose escalation data (Pri

  27. Slide 27: Key Investment Highlights

    Key Investment Highlights Developing next generation IO therapeutics, targeting key mechanisms of immunosuppression Multiple near-term clinical and pipeline milestones EOS-850 is a potential best-in-class selective A2AR antagonist with two confirmed PRs in Phase 1 single agent dose escalation Pipeli

iTeos Therapeutics — Investor Presentation (November 2020) on 6ix